Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 4 minute read Pharma Industry News Cloudbreak Pharma announces positive clinical results for vascularized pinguecula therapy CBT-004 shows significant efficacy and safety in Phase 2 trial for vascularized pinguecula; experts cite breakthrough in non-steroidal treatment. bySoujanya RaviJuly 21, 2025